ANI Pharmaceuticals Inc. (NASDAQ: ANIP) Insider Sells Shares Amidst Strong Generics Growth and Rare Disease Expansion

• A Senior Vice President at ANI Pharmaceuticals Inc. sold 500 shares of company stock for $77.95 each.
• ANI Pharmaceuticals Inc. is strategically expanding its focus into the rare disease market while maintaining a strong generics division.
• Recent product launches and a 28% growth in its generics division in 2025 highlight ANI Pharmaceuticals Inc.'s robust R&D and market strategy.

At ANI Pharmaceuticals Inc. (NASDAQ: ANIP), an insider transaction occurred on April 13, 2026. Cook Meredith, the Senior Vice President, General Counsel, and Secretary, sold 500 shares of common stock. The shares were sold at a price of $77.95 each, and Meredith now holds 78,890 shares in the company.

ANI Pharmaceuticals Inc. is a pharmaceutical company that develops, manufactures, and markets prescription medicines. The company operates a generics division that serves as a consistent source of revenue. It is also expanding its focus into the rare disease market, with its flagship asset being Cortrophin.

The company recently announced the launch of Carbamazepine Extended-Release Capsules, a generic version of Carbatrol®. According to IQVIA data, the total U.S. annual market for this product is approximately $65 million. This launch is part of the company's strategy to strengthen its generics portfolio in markets with limited competition.

ANI Pharmaceuticals Inc. also received FDA approval for and launched Isosorbide Mononitrate Tablet USP, a generic version of Monoket®. CEO Nikhil Lalwani notes these launches show the company's strong research and development capabilities. The goal is to maintain a steady introduction of new, high-quality products for patients.

As highlighted by Seeking Alpha, ANI Pharmaceuticals Inc.'s generics division grew 28% in 2025, reaching $384 million in revenues. This success helps fund the company's expansion into rare diseases. Shares of ANI Pharmaceuticals Inc. currently trade at $78.31, giving the company a market capitalization of approximately $1.76 billion.